Placental Pathology and Inflammatory Factor Analysis of OAPS
1 other identifier
observational
40
1 country
1
Brief Summary
This investigation is on placental pathological changes and inflammatory factors associated with obstetric antiphospholipid syndrome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2022
CompletedFirst Submitted
Initial submission to the registry
May 12, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 12, 2022
CompletedFirst Posted
Study publicly available on registry
May 18, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2023
CompletedMay 18, 2022
January 1, 2022
4 months
May 12, 2022
May 12, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
expression of ACC1 in placenta in pregnancy with/without antiphospholipid syndrome
in two years
Study Arms (1)
obstetric antiphospholipid syndrome
obstetric antiphospholipid syndrome 20 cases and normal pregnant women 20 cases
Interventions
Eligibility Criteria
pregnant women with antiphospholipid syndrome (diagnosed by experts with clinical evidence) and healthy pregnant women without antiphospholipid syndrome as a control group
You may qualify if:
- pregnant women with antiphospholipid syndrome (diagnosed by experts with clinical evidence) and healthy pregnant women without antiphospholipid syndrome as a control group
- consent to join this study and finish the informed consents
You may not qualify if:
- pregnant women with other autoimmune diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
PekingUPH
Beijing, China
Study Officials
- PRINCIPAL INVESTIGATOR
Jingjing Yang, doctor
Peking University People's Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Deputy chief physician
Study Record Dates
First Submitted
May 12, 2022
First Posted
May 18, 2022
Study Start
January 1, 2022
Primary Completion
May 12, 2022
Study Completion
December 31, 2023
Last Updated
May 18, 2022
Record last verified: 2022-01
Data Sharing
- IPD Sharing
- Will not share